Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Market Closed 03-21 16:00:00 EDT

0.7538

+0.0383

+5.35%

盘后0.7500

-0.0038-0.50%

19:07 EDT

High0.7538	Low0.7051	Vol1.06M
Open0.7068	D1 Closing0.7155	Amplitude6.81%
Mkt Cap94.83M	Tradable Cap94.77M	Total Shares125.80M
T/O783.85K	T/O Rate0.85%	Tradable Shares125.73M
P/B1.29	ROE-31.30%	EPS-0.21
52wk High2.31	52wk Low0.6600	P/E-3.52
Dividend0.00	Div.Yield0.00	ROA-20.35%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":0.7538,"timestamp":1742587200000,"preClose":0.7155,"halted":0,"volume":1063016,"hourTrading":{"tag":"盘后","latestPrice":0.75,"preClose":0.7538,"latestTime":"19:07 EDT","volume":135799,"amount":102343.34879,"timestamp":1742598428686},"delay":0,"floatShares":125727836,"shares":125801254,"eps":-0.214378,"marketStatus":"Market Closed","change":0.0383,"latestTime":"03-21 16:00:00 EDT","open":0.7068,"high":0.7538,"low":0.7051,"amount":783853.0098744,"amplitude":0.068064,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.214378,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":0.7155,"preHourTrading":{"tag":"盘前","latestPrice":0.7154,"preClose":0.7155,"latestTime":"09:29 EDT","volume":2299,"amount":1635.4045242700001,"timestamp":1742563740056},"postHourTrading":{"tag":"盘后","latestPrice":0.75,"preClose":0.7538,"latestTime":"19:07 EDT","volume":135799,"amount":102343.34879,"timestamp":1742598428686},"volumeRatio":2.4380473704565917,"impliedVol":1.0156,"impliedVolPercentile":0.544},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2521286014","title":"Atossa Therapeutics Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286014?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:57","pubTimestamp":1742561825,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of6cents a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to show no change in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q414E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS"],"gpt_icon":0},{"id":"2520134451","title":"Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520134451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520134451?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:13","pubTimestamp":1742476390,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUASQTZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2518712740","title":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518712740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518712740?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:04","pubTimestamp":1741701897,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other usesMarch 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ANNOUNCES PLANS TO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2518745265","title":"Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745265?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:25","pubTimestamp":1741695936,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics (ATOS) announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-to-pursue-metastatic-breast-cancer-for-z-endoxifen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-to-pursue-metastatic-breast-cancer-for-z-endoxifen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4079","BK4588","BK4551","Z","ATOS","BK4139","BK4585","LENZ"],"gpt_icon":0},{"id":"2509628335","title":"Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2509628335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509628335?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care. SEATTLE, Feb. 05, 2025  -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention . This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City.Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of young breast cancer patients, part","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","Z","CDC","ATOS","BK4588","BK4548","LENZ","BK4585","BK4079"],"gpt_icon":0},{"id":"2507676180","title":"Atossa Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507676180","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507676180?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 01:31","pubTimestamp":1738258260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 12:31 ET (17:31 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","LENZ"],"gpt_icon":0},{"id":"2507629754","title":"Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629754","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507629754?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 22:38","pubTimestamp":1738247937,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics  said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.Atossa shares were 9% lower in early trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ATOS","BK4139"],"gpt_icon":0},{"id":"2507628447","title":"Atossa Therapeutics - Will Not Be Pursuing an Appeal From Ptab Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628447?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2507628423","title":"Atossa Therapeutics - Responds to Ptab Ruling on U.S. Patent No. 11,572,334 and Announces Issuance of U.S. Patent No. 12,201,591","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628423?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2507284426","title":"Atossa Therapeutics - Decision Has No Impact on Formulations Currently in Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2507284426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507284426?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2505018141","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505018141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505018141?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 21:15","pubTimestamp":1737638100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUAC6BLQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2505018774","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505018774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505018774?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 21:15","pubTimestamp":1737638100,"startTime":"0","endTime":"0","summary":"SEATTLE, Jan. 23, 2025  -- Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows:. As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of -endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment landscape.Completion of the KARISMA-Endoxifen Phase 2 Study - One of the most significant milestones this year was the completion and announcement of results from our phase 2 KARISMA-Endoxifen Study. This study evaluated the ability of low doses o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-issues-letter-shareholders-131500934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","Z","LU1496350171.SGD","LENZ","E","BK4551","PK","OFS","BK4161","BK4201","BK4079","BK4135","FTV","BK4548","IE00BN0W2T93.GBP","BK4585","BK4543","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4218","LU1496350502.SGD","ATOS","BK4181"],"gpt_icon":0},{"id":"2505901982","title":"BRIEF-Atos estimates year-end liquidity at EUR 2.19 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2505901982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505901982?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 14:17","pubTimestamp":1737440225,"startTime":"0","endTime":"0","summary":"Jan 21  - Atos   :   * LIQUIDITY IS ESTIMATED AT 2,191 MILLION   * ESTIMATED 319 MILLION OF PAYMENTS RECEIVED FROM CUSTOMERS   * 240 MILLION OF NET PROCEEDS FROM THE SALE OF THE WORLDGRID BUSINESS UNIT   * 440 MILLION OF UNDRAWN REVOLVING CREDIT FACILITY    * YEAR-END CASH POSITION WOULD BE ESTIMATED AT 1,192 MILLIONSource text: [Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":1},{"id":"2495619096","title":"TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2495619096","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495619096?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 21:28","pubTimestamp":1735651680,"startTime":"0","endTime":"0","summary":"Tactile Systems Technology TCMD, a leader in innovative therapies for chronic conditions, has demonstrated consistent year-over-year revenue growth over the past three quarters. The company reported revenues of $72.1 million , $73.2 million  and $73.1 million  in the first, second and third quarters of 2024, respectively. While these figures reflect a commendable annual growth trajectory, a closer examination reveals a mix of positive advancements and persistent challenges shaping the overall revenue trend.One of the key favorable factors for investors is Tactile System’s significant outperformance in 2024 compared to its industry. In the past three months, TCMS’ shares have gained 20.5%, beating the Medical – Instruments’ decline of 2.8% and the S&P 500’s gain of 5.2%.The contrast is even more striking compared to key peers like TransMedics Group TMDX and Atossa Genetics ATOS, whose shares have plunged 59.1% and 33.3%, respectively. This relative strength suggests that Tactile Systems","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcmd-stock-rises-20-three-132800344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1804176565.USD","LU2286300806.USD","LU0082616367.USD","LU0557290698.USD","LU0943347566.SGD","LU2361044949.HKD","ATOS","LU2357305700.SGD","TCMD","BK4567","LU1551013425.SGD","LU1951200564.SGD","LU1989764748.USD","TMDX","LU1267930813.SGD","LU0353189763.USD","LU2756315318.SGD","BK4585","LU1720051108.HKD","LU0106261372.USD","LU0130102774.USD","BK4532","LU0251131958.USD","CRM","LU1823568750.SGD","BK4535","LU2461242641.AUD","LU1923623000.USD","LU1064131342.USD","LU1720051017.SGD","LU1814569148.SGD","LU0354030511.USD","LU2324357040.USD","BK4139","LU2244417387.USD","LU2265009873.SGD","LU2236285917.USD","LU1548497426.USD","LU0354030438.USD","LU0267386448.USD","BK4579","LU1496350502.SGD","BK4588","BK4550","LU0648001328.SGD","IE00BQXX3C00.GBP","LU1988902786.USD","LU0980610538.SGD","BK4548","LU2361045086.USD"],"gpt_icon":0},{"id":"2493425542","title":"Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493425542","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493425542?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 22:40","pubTimestamp":1734705609,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc.  one of those stocks right now?Let's take a closer look at the stock's year-to-date performance to find out.Atossa Genetics Inc. is a member of our Medical group, which includes 1020 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 .Based on the most recent data, ATOS has returned 11.4% so far this year. Meanwhile, stocks in the Medical group h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-genetics-atos-stock-outpacing-144009847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1066053197.SGD","IE00B3T34201.USD","BK4578","IE00BSNM7G36.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4568","LU1430594728.SGD","LU1571399168.USD","BK4585","LU2468319806.SGD","LU1066051498.USD","BK4550","LU0109394709.USD","BK4583","IE00B7SZLL34.SGD","BK4588","BK4566","LU1839511570.USD","IE00B19Z3581.USD","LU0234570918.USD","BK4532","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","ATOS","IE0002270589.USD","LU0289739699.SGD","LU2087621335.USD","LU1585245621.USD","GILD","LU0889565916.HKD","LU0058720904.USD"],"gpt_icon":0},{"id":"2491271473","title":"Atossa Therapeutics to present poster on Z-endoxifen at SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2491271473","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491271473?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 21:20","pubTimestamp":1734096036,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics  announced data describing the discovery of compounds that may be synergistic with -endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, on December 13, 2024. The data suggest that combination therapies with -endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer but require further study.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Atossa Therapeutics announces full result from KARISMA-Endoxifen trial. Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study. Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial. Atossa Therapeutics presents data from research investigating Z-Endoxifen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EWL56DETwmfBFfnXlOrIoQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EWL56DETwmfBFfnXlOrIoQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/atossa-therapeutics-present-poster-z-132036524.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-present-poster-z-132036524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4139","BK4551","BK4585","BK4079","ATOS","LENZ","Z","BK4588"],"gpt_icon":0},{"id":"2490383283","title":"Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2490383283","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490383283?lang=en_us&edition=full_marsco","pubTime":"2024-12-12 21:15","pubTimestamp":1734009300,"startTime":"0","endTime":"0","summary":"Insilico and Chemical Screening Identified Compounds that Synergize with -endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments. SEATTLE, Dec. 12, 2024  -- Atossa Therapeutics, Inc.  , a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced data describing the discovery of compounds that may be synergistic with -endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium  on December 13, 2024.“The discovery of new, synergistic compounds that could potentially complement the cancer preventing and fighting mechanism of -endoxifen showcases our continuing mission to transform the breast cancer paradigm,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “I","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R69GTF76Ararl7j3Fj06dg--~B/aD03MDt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/335e05a72b14d5230e84d9e4dbf7ebdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R69GTF76Ararl7j3Fj06dg--~B/aD03MDt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/335e05a72b14d5230e84d9e4dbf7ebdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-present-poster-describing-131500030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4201","BK4079","BK4585","ATOS","BK4588","BK4548","BK4551","Z","E","BK4139"],"gpt_icon":0},{"id":"2490854877","title":"Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854877?lang=en_us&edition=full_marsco","pubTime":"2024-12-11 21:15","pubTimestamp":1733922900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA2THJPY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2490854874","title":"Atossa Therapeutics: No Significant Differences in Adverse Events Were Observed Between 1 Mg Dose and Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854874?lang=en_us&edition=full_marsco","pubTime":"2024-12-11 21:15","pubTimestamp":1733922900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA2THJPY:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2490854869","title":"Atossa Therapeutics Announces Full Results From Phase 2 Karisma-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854869?lang=en_us&edition=full_marsco","pubTime":"2024-12-11 21:15","pubTimestamp":1733922900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA2THJPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0474},{"period":"1month","weight":-0.1416},{"period":"3month","weight":-0.2178},{"period":"6month","weight":-0.4837},{"period":"1year","weight":-0.5513},{"period":"ytd","weight":-0.2016}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.293861},{"month":2,"riseRate":0.538462,"avgChangeRate":0.099322},{"month":3,"riseRate":0.384615,"avgChangeRate":0.092765},{"month":4,"riseRate":0.25,"avgChangeRate":-0.074599},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.004454},{"month":6,"riseRate":0.583333,"avgChangeRate":0.133936},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.118738},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.056265},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036311},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.201299},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048676},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.116498}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction